Core Scientific's stock climbed 4.0% in pre-market trading, attempting a partial recovery after a sharp drop in the prior session even though the company announced a range of developments that investors generally viewed as positive.
At the center of the rebound is broad analyst enthusiasm surrounding the company's recently disclosed partnership with AMD. Several brokerage firms raised their price targets in response: Compass Point moved its target to $36 from $28, Macquarie raised its target to $38 from $35, Needham increased its target to $35 from $29, and Canaccord boosted its target to $36 from $30. Each firm retained either Buy or Outperform ratings.
The AMD agreement secures roughly 529 megawatts of critical IT capacity across five Core Scientific campuses under 15-year lease arrangements that include 2.5% annual escalators. AMD also holds the option to expand that footprint to as much as 2.5 gigawatts. Core Scientific's management has estimated the contracted revenue opportunity associated with the relationship could exceed $24 billion in total. Needham characterized the deal as a "large quality lease" and suggested that recent weakness in Core Scientific shares was tied to sell-offs across the AI infrastructure sector rather than company-specific deterioration.
Other developments adding to investor interest included Core Scientific's July 29 appointment of Mark W. Adams to the board of directors. Adams brings more than three decades of experience in AI infrastructure, semiconductors, and enterprise hardware, with prior roles including President and CEO of Penguin Solutions and President of Micron Technology. Market observers interpreted the board addition as a governance enhancement aligned with the company's pivot toward high-density AI colocation.
However, the positive headlines were tempered by several cautionary signals. Keefe Bruyette downgraded the stock to Market Perform and set a $25 target, calling out elevated execution risk in the second half of 2026. Core Scientific's adjusted EBITDA for the quarter was $41.1 million, coming in below the $52.7 million consensus estimate. Additionally, the company's Chief Legal and Administrative Officer executed a planned sale of roughly $209,000 worth of shares on July 27 under a pre-arranged trading plan.
The broader market backdrop offered some support for risk appetite in tech and AI infrastructure names. The Nasdaq rose by 0.8% and the S&P 500 gained 0.4%, a constructive tone that helped underpin the pre-market move in Core Scientific's shares. Even with the rebound, the stock remains beneath its 52-week high of $30.46 and below the most bullish analyst targets in the $36 to $38 range.
Summary
Core Scientific staged a pre-market recovery after a prior-session sell-off, driven largely by multiple analyst price-target increases tied to a significant AMD colocation agreement, a second-quarter revenue beat, and a strategic board appointment. Offsetting items included an adjusted EBITDA miss, a broker downgrade citing execution risk, and an insider share sale.
Key points
- Analyst upgrades - Several firms raised price targets and maintained Buy or Outperform ratings after Core Scientific disclosed a major lease agreement with AMD.
- Material AMD deal - The agreement initially covers about 529 megawatts across five campuses under 15-year leases with 2.5% annual escalators and includes AMD's option to expand to 2.5 gigawatts, a potential contracted revenue opportunity that management estimates could exceed $24 billion.
- Market context - A modestly firmer Nasdaq and S&P 500 supported risk-taking in technology and AI infrastructure sectors during pre-market trading.
Risks and uncertainties
- Execution risk - Keefe Bruyette highlighted elevated execution risk in the second half of 2026, a concern that could affect operational delivery and investor confidence in the sector.
- Financial performance shortfall - Adjusted EBITDA of $41.1 million missed the $52.7 million consensus, indicating near-term profitability metrics fell short of expectations and may pressure sentiment.
- Insider selling - The Chief Legal and Administrative Officer sold about $209,000 of shares under a pre-arranged plan, an action that can add caution among shareholders despite the plan's pre-arranged nature.